drugset / Trial / NCT03594552

Modulation of the Brain Excitatory/Inhibitory (E/I) Balance in Autism Spectrum Disorder (ASD)

NCT03594552

Completed 87 enrolled King's College London
RandomizedCrossoverDouble-blindBasic science

Summary

This study investigates the brain response to a single acute dose of Arbaclofen, the R-enantiomer of the GABA-B agonist Baclofen, compared to a single dose of placebo in healthy men with and without autism spectrum disorder.

Timeline

Start
2018-02-01
Primary completion
2020-03-12
Completion
2020-03-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Arbaclofen Small molecule 15 mg Oral
Subject Arbaclofen Small molecule 30 mg Oral